Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer

1 Jan 2018

Abstract excerpt

Background: Biomarkers predicting response to bevacizumab in breast cancer are still missing. Since epigenetic modifications can contribute to an aberrant regulation of angiogenesis and treatment resistance, we investigated the influence of DNA methylation patterns on bevacizumab efficacy. Methods: Genome-wide methylation profiling using the Illumina Infinium HumanMethylation450 BeadChip was performed in archival...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to Cancer Genomics and Diagnostics
Share to Cancer Treatment and Pharmacology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29721079
DOI: 10.7150/thno.23544

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast CancerPMID 29721079Read ↗

An integrated ‘omics approach highlights the role of epigenetic events to explain and predict response to neoadjuvant chemotherapy and bevacizumabSemantic proximity Read ↗

Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancerSemantic proximity Read ↗

A seven-gene CpG-island methylation panel predicts breast cancer progressionSemantic proximity Read ↗

Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell lung cancerSemantic proximity Read ↗

Multigene methylation analysis of enriched circulating tumor cells associates with poor progression-free survival in metastatic breast cancer patientsSemantic proximity Read ↗

DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic MelanomaSemantic proximity Read ↗

Whole-genome bisulfite sequencing of cell-free DNA identifies signature associated with metastatic breast cancerSemantic proximity Read ↗

DNA methylation status as a biomarker of anti‐epidermal growth factor receptor treatment for metastatic colorectal cancerSemantic proximity Read ↗

Epigenetic biomarkers for clinical outcomes and mechanisms driving emergence of drug resistance in ovarian cancerSemantic proximity Read ↗

Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 TrialSemantic proximity Read ↗

Deep Learning Can Predict Bevacizumab Therapeutic Effect and Microsatellite Instability Directly from Histology in Epithelial Ovarian CancerSemantic proximity Read ↗

Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.